Mesothelioma Treatment Centers

When a doctor tells you or someone you love that mesothelioma is the diagnosis, the next question is almost always: where do we go from here? That answer matters more than many patients realize. According to the National Cancer Institute (NCI), specialized cancer centers that treat high volumes of rare cancers like mesothelioma consistently deliver better surgical outcomes, broader clinical trial access, and more coordinated care than general community hospitals. For a disease affecting roughly 3,000 Americans each year, finding the right facility is not a formality. It's a medical decision with real consequences for survival.

Mesothelioma treatment centers are hospitals or cancer programs with dedicated, multidisciplinary teams that specialize in malignant mesothelioma. These teams typically include thoracic surgeons experienced in procedures like extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D), medical oncologists who manage systemic therapies, radiation oncologists, pulmonologists, pathologists trained in rare tumor diagnosis, and palliative care specialists. The NCI formally designates 71 U.S. cancer centers as of 2025, and many of the strongest mesothelioma programs operate within these institutions.

The difference between a general hospital and a dedicated mesothelioma center can be measured in months. A 2019 analysis published in the Journal of Thoracic Oncology found that patients with pleural mesothelioma treated at high-volume thoracic surgery centers had a median overall survival of 18.5 months, compared to 13.2 months at low-volume centers. That gap reflects not just surgical skill, but the accumulated institutional knowledge that comes from treating dozens of mesothelioma cases each year rather than a handful.

This entry profiles the characteristics of top-tier mesothelioma treatment programs, explains how to evaluate a center's qualifications, and outlines what you can expect from the care process at a specialized facility.

Mesothelioma treatment centers generally fall into three tiers, and understanding the difference helps you ask the right questions when seeking care.

NCI-Designated Comprehensive Cancer Centers represent the highest tier. These 57 institutions (a subset of the 71 total NCI-designated centers) have demonstrated excellence across research, training, and patient care. Programs at Memorial Sloan Kettering Cancer Center in New York, MD Anderson Cancer Center in Houston, and the University of Chicago Medicine are among the most frequently cited for mesothelioma volume and outcomes. Memorial Sloan Kettering, for example, has published landmark research on heated intraoperative chemotherapy (HIOC) and maintains one of the largest mesothelioma surgical series in the world.

Academic Medical Centers with Dedicated Thoracic Programs form a second tier. Institutions like Brigham and Women's Hospital (Harvard Medical School) in Boston, the University of Pennsylvania's Abramson Cancer Center, and Baylor College of Medicine in Houston operate high-volume mesothelioma programs that contribute substantially to published research. Brigham and Women's was the site of pioneering EPP research led by Dr. David Sugarbaker, whose work through the 1990s and 2000s helped define modern surgical standards for pleural mesothelioma.

Regional Referral Centers make up a third category. These community-based or regional hospitals may not publish research or enroll patients in Phase I trials, but they maintain relationships with NCI-designated centers and can provide high-quality care for patients who cannot travel. They are particularly important for peritoneal mesothelioma patients seeking cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy), a procedure now available at more than 50 U.S. hospitals.

Consider a patient in rural Ohio who receives a mesothelioma diagnosis at a local hospital. The pathology report says 'epithelioid pleural mesothelioma,' but the treating physician has never managed this disease. That scenario plays out hundreds of times each year, and it illustrates why where you get your diagnosis can be just as important as where you receive treatment.

Top mesothelioma centers offer specialized diagnostic services that general hospitals often can't match. Mesothelioma is notoriously difficult to distinguish from other cancers, particularly lung adenocarcinoma and metastatic carcinoma. According to the American Cancer Society, accurate diagnosis requires immunohistochemical staining with markers like calretinin, WT-1, and D2-40, interpreted by pathologists who regularly see mesothelioma specimens. A misdiagnosis means the wrong treatment, and the wrong treatment wastes irreplaceable time.

Leading centers also offer advanced imaging interpretation. PET-CT scanning, MRI with dedicated thoracic protocols, and endobronchial ultrasound (EBUS) are used not just to confirm disease but to stage it accurately, a prerequisite for determining whether a patient is a surgical candidate. The staging process at specialized centers follows the 8th edition AJCC/UICC staging system, updated in 2017, which refined T-stage criteria for pleural mesothelioma and improved prognostic accuracy.

Molecular profiling is increasingly standard at top centers. Genomic testing through platforms like Foundation Medicine's FoundationOne CDx can identify BAP1 mutations, NF2 loss, and other alterations that may predict response to immunotherapy or qualify patients for targeted clinical trials. The NCI's Cancer Genome Atlas (TCGA) project has contributed to understanding these molecular subtypes, and major centers apply this knowledge directly to treatment planning.

The treatment philosophy at a top mesothelioma center differs fundamentally from what you'd find at a general hospital. Specialized programs use a tumor board model, meaning your case is reviewed by a team of specialists before any treatment decision is made. According to the NCI, multidisciplinary tumor boards improve treatment planning consistency and help identify clinical trial eligibility that a single physician might miss.

Surgical treatment at high-volume centers reflects decades of refinement. For pleural mesothelioma, the two primary operations are extrapleural pneumonectomy (EPP), which removes the affected lung along with the pleura, pericardium, and diaphragm, and pleurectomy/decortication (P/D), which preserves the lung while removing the pleural lining. A 2020 meta-analysis in Annals of Translational Medicine found that P/D was associated with lower 30-day mortality than EPP (2.9% vs. 6.8%), and many leading centers now favor lung-sparing approaches for appropriate candidates. Surgeons at centers like the Thoracic Oncology Program at UCSF and the Mesothelioma Program at Brigham and Women's Hospital perform 20 or more of these procedures annually, a volume associated with significantly better outcomes.

Systemic therapy at specialized centers goes well beyond the standard first-line regimen of cisplatin and pemetrexed, which has been the backbone of mesothelioma chemotherapy since the pivotal Vogelzang et al. trial published in the Journal of Clinical Oncology in 2003. Following the 2020 CheckMate 743 trial results, the FDA approved nivolumab plus ipilimumab as a first-line option for unresectable pleural mesothelioma. Top centers were among the first to integrate this immunotherapy combination into clinical practice, and they continue to enroll patients in trials testing novel agents like tazemetostat, lurbinectedin, and CAR-T cell therapies targeting mesothelin.

For peritoneal mesothelioma, cytoreductive surgery combined with HIPEC has transformed outcomes at specialized centers. A 2020 study from the Washington Cancer Institute, one of the pioneering HIPEC programs, reported median survival exceeding 50 months in selected peritoneal mesothelioma patients treated with cytoreduction and HIPEC, compared to historical medians of 12 to 14 months with systemic chemotherapy alone. This procedure requires surgeons with extensive HIPEC experience and is not available at most hospitals.

Radiation therapy at top centers uses modern techniques including intensity-modulated radiation therapy (IMRT) and proton beam therapy, which can deliver high doses to the pleural surface while sparing adjacent heart and lung tissue. The SMART protocol (Surgery for Mesothelioma After Radiation Therapy), developed at Princess Margaret Cancer Centre in Toronto, delivers hypofractionated radiation before EPP and has shown promising results in early-phase trials.

Your prognosis at a specialized mesothelioma center is shaped by several factors that go beyond the cancer itself. Cell type matters enormously: patients with epithelioid mesothelioma, the most common subtype, have a median survival of 14 to 19 months with modern treatment, while those with sarcomatoid or biphasic disease face more limited options, according to data from the SEER database analyzed by the NCI.

Volume and experience at your chosen center directly affect outcomes. A 2022 analysis in JAMA Surgery confirmed that patients undergoing complex thoracic surgery at hospitals performing more than 20 such operations annually had significantly lower complication rates and shorter hospital stays. For a disease where surgical complications can set back systemic treatment by weeks, this difference is clinically meaningful.

Access to clinical trials may be the most underappreciated prognostic factor. As of early 2025, ClinicalTrials.gov lists more than 60 actively recruiting trials for mesothelioma, most of them enrolling exclusively at NCI-designated centers or academic medical centers with dedicated mesothelioma programs. Patients who enroll in trials often receive experimental agents not yet available outside the research setting, and some of those agents, like nivolumab, eventually become standard of care. Getting to a specialized center early maximizes your chances of qualifying for these studies.

Choosing a mesothelioma treatment center is not a one-time decision. Your needs will change as your disease evolves, and the best centers anticipate that. Palliative care integration is a hallmark of top programs. The 2010 NEJM study by Temel et al., conducted at Massachusetts General Hospital, demonstrated that early palliative care alongside standard oncology treatment improved quality of life and, notably, extended survival by nearly three months in lung cancer patients. Most major mesothelioma centers have since adopted integrated palliative care models.

Practical support matters too. Top centers offer financial counseling, social work services, patient navigation programs, and connections to legal resources for patients whose mesothelioma is linked to asbestos exposure. Many patients are eligible for asbestos trust fund compensation or legal settlements, and the social work teams at specialized centers can help facilitate those referrals.

If you can't travel to a major center for ongoing treatment, a hybrid approach is worth discussing with your oncologist. Many patients receive their surgical evaluation and treatment planning at a high-volume center, then return to a local oncologist for chemotherapy infusions or immunotherapy maintenance. Telemedicine consultations, now widely available at NCI-designated centers following the expansion during the COVID-19 pandemic, make it easier to maintain a relationship with a mesothelioma specialist without repeated long-distance travel.

'The most important thing patients can do is get a second opinion at a center that sees mesothelioma regularly,' said Dr. Hedy Kindler, director of the mesothelioma program at the University of Chicago Medicine and a lead investigator on multiple mesothelioma trials. 'The treatment landscape has changed dramatically in five years, and not every oncologist has kept pace with those changes.'